(Total Views: 542)
Posted On: 04/02/2020 1:52:45 PM
Post# of 153988
Re: LaundryMoney #24860
Summary (upon first listening, probably missed/left out a couple of things)
- 10 patients extremely ill, many of them had renal failure, all of them had been on (hydroxo)chloroquine before (?), profound immunological abnormalities; all 8 patients (2 yet to be evaluated) had immunological response, 1 discharged, couple of patients got out of ICU; (in comparison, in study of China with comparable patients, 31/32 died).
- Two effects of leronlimab: (1) Restoring the immune cells back to normal range; (2) Quieting the cytokine storm (70-90% reduction);
- Results with mild/moderate population should be good, probably even better and prevent severe disease.
- Many hospitals interested to conduct study (Harvard, Cornell, San Francisco...), should start today or tomorrow.
- Manufacturing: working with ACG and Samsung.
-
- 10 patients extremely ill, many of them had renal failure, all of them had been on (hydroxo)chloroquine before (?), profound immunological abnormalities; all 8 patients (2 yet to be evaluated) had immunological response, 1 discharged, couple of patients got out of ICU; (in comparison, in study of China with comparable patients, 31/32 died).
- Two effects of leronlimab: (1) Restoring the immune cells back to normal range; (2) Quieting the cytokine storm (70-90% reduction);
- Results with mild/moderate population should be good, probably even better and prevent severe disease.
- Many hospitals interested to conduct study (Harvard, Cornell, San Francisco...), should start today or tomorrow.
- Manufacturing: working with ACG and Samsung.
-
(8)
(0)
